Skip to Content
Merck
  • Aurora kinase A regulates cancer-associated RNA aberrant splicing in breast cancer.

Aurora kinase A regulates cancer-associated RNA aberrant splicing in breast cancer.

Heliyon (2023-07-07)
Sisi Li, Yangfan Qi, Jiachuan Yu, Yuchao Hao, Lingzhi Xu, Xudong Ding, Minghui Zhang, Jingshu Geng
ABSTRACT

The contribution of oncogenes to tumor-associated RNA splicing and the relevant molecular mechanisms therein require further elaboration. Here, we show that oncogenic Aurora kinase A (AURKA) promotes breast cancer-related RNA aberrant splicing in a context-dependent manner. AURKA regulated pan-breast cancer-associated RNA splicing events including GOLGA4, RBM4 and UBQLN1. Aberrant splicing of GOLGA4 and RBM4 was closely related to breast cancer development. Mechanistically, AURKA interacted with the splicing factor YBX1 and promoted AURKA-YBX1 complex-mediated GOLGA4 exon inclusion. AURKA binding to the splicing factor hnRNPK promoted AURKA-hnRNPK complex-mediated RBM4 exon skipping. Analysis of clinical data identified an association between the AURKA-YBX1/hnRNPK complex and poor prognosis in breast cancer. Blocking AURKA nuclear translocation with small molecule drugs partially reversed the oncogenic splicing of RBM4 and GOLGA4 in breast cancer cells. In summary, oncogenic AURKA executes its function on modulating breast cancer-related RNA splicing, and nuclear AURKA is distinguished as a hopeful target in the case of treating breast cancer.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Aurora-A Kinase antibody, Mouse monoclonal, clone 35C1, purified from hybridoma cell culture